Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

Please provide your email address to receive an email when new articles are posted on . Retinal implants have a history of challenges, and questions remain about their utility. A bioengineered RPE ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...